New Antiseizure Medication Approved

• Autores: Diane S. Aschenbrenner
• Localización: American Journal of Nursing, ISSN 0002-936X, Vol. 114, Nº. 3, 2014, págs. 22-23
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • * Eslicarbazepine acetate (Aptiom) is a new voltage-gated sodium channel inhibitor approved for use in the treatment of partial-onset seizures. It's used as part of combination therapy.

    * The most common adverse effects are similar to those of many other antiepileptic drugs and include central nervous system and gastrointestinal effects. The drug also carries risks of serious skin reactions, drug reactions with eosinophilia and systemic symptoms, anaphylaxis, significant hyponatremia, and liver injury.